#ocrevus (1 Posts)
-
Roche’s $7.6 Billion Drug Just Hit a Wall—Here’s Why That Matters Roche's Ocrevus, a leading MS treatment, showed no added benefits at higher doses in trials, impacting future sales projections.
Hot Topics